Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer

Supplemental Digital Content is available in the text Objective: This study compared outcomes of patients with esophageal cancer and clinically complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) undergoing active surveillance or immediate surgery. Background: Since nearly one-third of patients with esophageal cancer show pathologically complete response after nCRT according to CROSS regimen, the oncological benefit of immediate surgery in cCR is topic of debate. Methods: Patients with cCR based on endoscopic biopsies and endoscopic ultrasonography with fine-needle aspiration initially declining or accepting immediate surgery after nCRT were identified between 2011 and 2018. Primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), rate and timing of distant dissemination, and postoperative outcomes. Results: Some 98 patients with cCR were identified: 31 in the active surveillance- and 67 in the immediate surgery group with median followup of survivors of 27.7 and 34.8 months, respectively. Propensity score matching resulted in 2 comparable groups (n = 29 in both groups). Patients undergoing active surveillance or immediate surgery had a 3-year OS of 77% and 55% (HR 0.41; 95% CI 0.14–1.20, P = 0.104), respectively. The 3-year PFS was 60% and 54% (HR 1.08; 95% CI 0.44–2.67, P = 0.871), respectively. Patients undergoing active surveillance or immediate surgery had a comparable distant dissemination rate (both groups 28%), radical resection rate (both groups 100%), and severity of postoperative complications (Clav- ien-Dindo grade ≥ 3: 43% vs 45%, respectively). Conclusion: In this retrospective study, OS and PFS in patients with cCR undergoing active surveillance or immediate surgery were not significantly different. Active surveillance with postponed surgery for recurrent disease was not associated with a higher distant dissemination rate or more severe adverse postoperative outcomes.

[1]  E. Steyerberg,et al.  Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. , 2018, The Lancet. Oncology.

[2]  J. Lagergren,et al.  Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS) , 2018, Annals of Surgical Oncology.

[3]  E. Steyerberg,et al.  Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial , 2018, BMC Cancer.

[4]  E. Steyerberg,et al.  Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Chang,et al.  Benchmarking Complications Associated with Esophagectomy , 2017, Annals of surgery.

[6]  J. Ajani,et al.  Final Results of NRG Oncology RTOG 0246: An Organ‐Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  E. Steyerberg,et al.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. , 2015, The Lancet. Oncology.

[8]  Arnulf H Hölscher,et al.  International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). , 2015, Annals of surgery.

[9]  E. Steyerberg,et al.  Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol , 2015, JMIR Research Protocols.

[10]  Sung-Bae Kim,et al.  Role of surgical resection in complete responders on FDG‐PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma , 2014, Journal of surgical oncology.

[11]  C. Mariette,et al.  Is There a Role for Surgery for Patients with a Complete Clinical Response after Chemoradiation for Esophageal Cancer? An Intention-to-Treat Case-Control Study , 2013, Annals of surgery.

[12]  J. Ajani,et al.  Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation , 2013, Oncology.

[13]  A. Ruol,et al.  Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary? , 2013, Journal of Gastrointestinal Surgery.

[14]  B. O'neill,et al.  Targeting therapy for esophageal cancer in patients aged 70 and over. , 2013, Journal of geriatric oncology.

[15]  J. Ajani,et al.  Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation , 2012, Oncology.

[16]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[17]  C. Castoro,et al.  Systematic review of health-related quality of life after esophagectomy for esophageal cancer. , 2011, World journal of gastroenterology.

[18]  Y. Doki,et al.  Prognostic Value of Endoscopic Biopsy Findings After Induction Chemoradiotherapy With and Without Surgery for Esophageal Cancer , 2011, Annals of Surgery.

[19]  J. Hagen,et al.  Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. , 2010, Journal of the American College of Surgeons.

[20]  S. Meijer,et al.  The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer , 2009, Annals of surgery.

[21]  T. Djärv,et al.  Predictors of postoperative quality of life after esophagectomy for cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Meijer,et al.  Anti-β1 Integrin Antibody Reduces Surgery-Induced Adhesion of Colon Carcinoma Cells to Traumatized Peritoneal Surfaces , 2008, Annals of surgery.

[23]  J. Ajani,et al.  A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. , 2007, International journal of radiation oncology, biology, physics.

[24]  T. Conroy,et al.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Mats Lindblad,et al.  Risk Factors for Complications After Esophageal Cancer Resection: A Prospective Population-Based Study in Sweden , 2006, Annals of surgery.

[26]  R. D'Agostino Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[27]  Nils Lehmann,et al.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Sprangers,et al.  Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[30]  Y. Tachimori,et al.  Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. , 2009, The Journal of thoracic and cardiovascular surgery.

[31]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.

[32]  Ara A Vaporciyan,et al.  Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. , 2002, The Journal of thoracic and cardiovascular surgery.

[33]  N. Gül,et al.  Uva-dare (digital Academic Repository) Surgery-induced Reactive Oxygen Species Enhance Colon Carcinoma Cell Binding by Disrupting the Liver Endothelial Cell Lining Surgery-induced Reactive Oxygen Species Enhance Colon Carcinoma Cell Binding by Disrupting the Liver Endothelial Cell Lining , 2022 .

[34]  M. Makuuchi,et al.  The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience , 2009, Annals of surgery.